ReviewViruses2019
Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors.
Review in Viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 75 citations in OpenAlex.
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Anti-HCV NS2-3 potential of selected plant bioactive compounds revealed by docking, simulation and DFT.Scientific reports · 2026Article
- Discovery of Small Molecules Targeting Norovirus 3CL Protease by Multi-Stage Virtual Screening.International journal of molecular sciences · 2025Article
- Regulation of NS5B Polymerase Activity of Hepatitis C Virus by Target Specific Phytotherapeutics: An In-Silico Molecular Dynamics Approach.Cell biochemistry and biophysics · 2024Article
- An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations.Science translational medicine · 2024Article
- Article
- Article
- Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication.Virus research · 2023Article
- Network pharmacology and bioinformatics analysis identifies potential therapeutic targets ofFrontiers in endocrinology · 2023Article
- Potent Protease Inhibitors of Highly Pathogenic Lagoviruses: Rabbit Hemorrhagic Disease Virus and European Brown Hare Syndrome Virus.Microbiology spectrum · 2022Article
- Potential Antiviral Action of Alkaloids.Molecules (Basel, Switzerland) · 2022Review
- In-Silico Exploration of Plant Metabolites as Potential Remedies of Norovirus.Advances in virology · 2022Article
- Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study.Frontiers in chemistry · 2022Article
- Could Probiotics and Postbiotics Function as "Silver Bullet" in the Post-COVID-19 Era?Probiotics and antimicrobial proteins · 2021Review
- Precursors of Viral Proteases as Distinct Drug Targets.Viruses · 2021Review
- A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo.Viruses · 2021Article
- Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2.Journal of pharmacological sciences · 2021Article
- Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.Molecular diversity · 2021Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Proteases are a major enzyme group playing important roles in a wide variety of biological processes in life forms ranging from viruses to mammalians. The aberrant activity of proteases can lead to various diseases; consequently, host proteases have been the focus of intense investigation as potential therapeutic targets. A wide range of viruses encode proteases which play an essential role in viral replication and, therefore, constitute attractive targets for the development of antiviral therapeutics. There are numerous examples of successful drug development targeting cellular and viral proteases, including antivirals against human immunodeficiency virus and hepatitis C virus. Most FDA-approved antiviral agents are peptidomimetics and macrocyclic compounds that interact with the active site of a targeted protease. Norovirus proteases are cysteine proteases that contain a chymotrypsin-like fold in their 3D structures. This review focuses on our group's efforts related to the development of norovirus protease inhibitors as potential anti-norovirus therapeutics. These protease inhibitors are rationally designed transition-state inhibitors encompassing dipeptidyl, tripeptidyl and macrocyclic compounds. Highly effective inhibitors validated in X-ray co-crystallization, enzyme and cell-based assays, as well as an animal model, were generated by launching an optimization campaign utilizing the initial hit compounds. A prodrug approach was also explored to improve the pharmacokinetics (PK) of the identified inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.